Cutaneous complications of molecular targeted therapy used in oncology

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Molecular targeted therapies have advanced cancer treatment over recent decades.
• These therapies target specific molecular changes in cancer cells.
• Common agents include epidermal growth factor receptors (EGFR) inhibitors, multi-targeted tyrosine kinase inhibitors, and monoclonal antibodies.

Purpose of the Study:

• To highlight the significant cutaneous adverse reactions associated with molecular targeted cancer therapies.
• To emphasize the impact of these skin toxicities on patient quality of life and treatment adherence.
• To underscore the necessity for oncologists and dermatologists to be proficient in managing these side effects.

Main Methods:

• Review of adverse event profiles for common molecular targeted therapies.
• Analysis of the clinical impact of cutaneous complications.
• Synthesis of current knowledge on managing treatment-related skin toxicities.

Main Results:

• Molecular targeted therapies frequently cause severe skin adverse reactions.
• These reactions can be dose-limiting, leading to treatment interruptions.
• Adverse cutaneous events significantly affect patient quality of life.

Conclusions:

• Effective management of skin toxicities is essential for successful molecular targeted therapy.
• Oncologists and dermatologists require specialized knowledge to address these dermatologic complications.
• Proactive management strategies are key to optimizing patient outcomes and treatment adherence.